Polycystic ovary syndrome and cardiometabolic risk

Opportunities for cardiovascular disease prevention

Olatokunbo Osibogun, Oluseye Ogunmoroti, Erin Donnelly Michos

Research output: Contribution to journalReview article

Abstract

Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.

Original languageEnglish (US)
JournalTrends in Cardiovascular Medicine
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Polycystic Ovary Syndrome
Cardiovascular Diseases
Oligomenorrhea
Hirsutism
Carotid Intima-Media Thickness
Glucose Intolerance
Amenorrhea
Acne Vulgaris
Dyslipidemias
Mood Disorders
C-Reactive Protein
Infertility
Insulin Resistance
Life Style
Coronary Vessels
Hypertension
Calcium
Weights and Measures

Keywords

  • Cardiovascular risk
  • Insulin resistance
  • Polycystic ovarian syndrome
  • Prevention
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Polycystic ovary syndrome and cardiometabolic risk : Opportunities for cardiovascular disease prevention. / Osibogun, Olatokunbo; Ogunmoroti, Oluseye; Michos, Erin Donnelly.

In: Trends in Cardiovascular Medicine, 01.01.2019.

Research output: Contribution to journalReview article

@article{82537b31dacd454e897ac25ce4f273f5,
title = "Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention",
abstract = "Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.",
keywords = "Cardiovascular risk, Insulin resistance, Polycystic ovarian syndrome, Prevention, Women",
author = "Olatokunbo Osibogun and Oluseye Ogunmoroti and Michos, {Erin Donnelly}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.tcm.2019.08.010",
language = "English (US)",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Polycystic ovary syndrome and cardiometabolic risk

T2 - Opportunities for cardiovascular disease prevention

AU - Osibogun, Olatokunbo

AU - Ogunmoroti, Oluseye

AU - Michos, Erin Donnelly

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.

AB - Although polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women, its etiology is not entirely understood. Clinical symptoms of PCOS include acne, amenorrhea or oligomenorrhea, hirsutism, infertility, and mood disorders, which tend to be the primary focus of clinical management. However, the impact of PCOS on future cardiovascular disease (CVD) risk should not be overlooked, and opportunities to implement CVD prevention strategies in these women should be given high priority. The pathogenesis of PCOS commonly involves insulin resistance which leads to several cardiometabolic abnormalities (e.g., dyslipidemia, hypertension, glucose intolerance, diabetes, and metabolic syndrome), thereby putting women at an increased risk for CVD. Prior studies have found that subclinical CVD markers such as coronary artery calcium scores, C-reactive protein, carotid intima-media thickness, and endothelial dysfunction are more likely to be increased in women with PCOS. While the associations between PCOS and cardiometabolic abnormalities have been well established, whether PCOS is associated with subclinical and clinical CVD, independently of these CVD risk factors, is not entirely clear. Lifestyle interventions and weight management may mitigate some of these future CVD risks and should be encouraged. This review summarizes the literature on PCOS and CVD risk factors and provides recommendations that would aid clinicians in the management of these risk factors.

KW - Cardiovascular risk

KW - Insulin resistance

KW - Polycystic ovarian syndrome

KW - Prevention

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=85071968166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071968166&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2019.08.010

DO - 10.1016/j.tcm.2019.08.010

M3 - Review article

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

ER -